German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.

BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy to offer cancer treatments using the modality.

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ongoing patent litigation.

Photo: wolfgang rattay/Reuters BioNTech BNTX 1.61% will acquire all shares of CureVac CVAC 0.93% after the two sides reached an agreement in a deal valued around $1.25 billion.

CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.

BioNTech's all-stock acquisition of CureVac is expected to create long-term value for shareholders of both companies, building on BioNTech's proven track record in mRNA research, development ...

CureVac (CVAC) stock jumps as BioNTech (BNTX) agrees to acquire in an all-stock deal worth $1.25B. Read more here.

Moderna is suing Pfizer and BioNTech, accusing the companies of infringing on Moderna’s patents when they developed their own COVID-19 vaccine.

BioNTech has announced that it will be expanding its messenger RNA (mRNA) capabilities by acquiring CureVac for approximately $1.25bn. The deal is aimed at strengthening BioNTech’s research, ...

Throughout the last three months, 11 analysts have evaluated BioNTech (NASDAQ:BNTX), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings ...

BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers (NYSE: BMY) Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer ...